Zai Lab Stock Performance
| ZLAB Stock | USD 18.55 0.05 0.27% |
The firm maintains a market beta of 0.95, which attests to possible diversification benefits within a given portfolio. Zai Lab returns are very sensitive to returns on the market. As the market goes up or down, Zai Lab is expected to follow. At this point, Zai Lab has a negative expected return of -0.79%. Please make sure to check out Zai Lab's kurtosis, and the relationship between the value at risk and rate of daily change , to decide if Zai Lab performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Zai Lab has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.27 | Five Day Return 2.43 | Year To Date Return 7.04 | Ten Year Return (33.58) | All Time Return (33.58) |
1 | Why Zai Lab Limited Depositary Receipt stock is considered a top pick - newser.com | 10/23/2025 |
2 | Disposition of 14328 shares by Edmondson Frazor Titus Iii of Zai Lab at 19.78 subject to Rule 16b-3 | 11/21/2025 |
3 | Zai Lab Remains a Buy Amid Strong Commercial and Pipeline Momentum - MSN | 12/02/2025 |
4 | Zai Lab starts global Phase 11b ZL-1503 atopic dermatitis trial - Stock Titan | 12/08/2025 |
5 | Disposition of 303378 shares by Ying Du of Zai Lab subject to Rule 16b-3 | 12/10/2025 |
6 | Acquisition by Ying Du of 377520 shares of Zai Lab subject to Rule 16b-3 | 12/11/2025 |
7 | Disposition of 8651 shares by Edmondson Frazor Titus Iii of Zai Lab at 17.14 subject to Rule 16b-3 | 12/16/2025 |
8 | How Investors May Respond To Zai Lab Advancing ZL-1503 Into Global Phase 11b Atopic Dermatitis Trial | 12/19/2025 |
9 | FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug | 12/23/2025 |
10 | Disposition of 21000 shares by Amado Rafael of Zai Lab subject to Rule 16b-3 | 12/30/2025 |
11 | Disposition of 10787 shares by Amado Rafael of Zai Lab at 17.432 subject to Rule 16b-3 | 12/31/2025 |
12 | Assessing Zai Lab Valuation After Recent Share Price Volatility | 01/06/2026 |
13 | UBS Gives Zai Lab a Buy Rating | 01/09/2026 |
| Begin Period Cash Flow | 791.3 M | |
| Total Cashflows From Investing Activities | -375.2 M |
Zai Lab Relative Risk vs. Return Landscape
If you would invest 3,123 in Zai Lab on October 13, 2025 and sell it today you would lose (1,268) from holding Zai Lab or give up 40.6% of portfolio value over 90 days. Zai Lab is currently does not generate positive expected returns and assumes 2.514% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Zai, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zai Lab Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zai Lab's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zai Lab, and traders can use it to determine the average amount a Zai Lab's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3151
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZLAB |
Based on monthly moving average Zai Lab is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zai Lab by adding Zai Lab to a well-diversified portfolio.
Zai Lab Fundamentals Growth
Zai Stock prices reflect investors' perceptions of the future prospects and financial health of Zai Lab, and Zai Lab fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zai Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | 1.57 B | ||||
| Shares Outstanding | 110.59 M | ||||
| Price To Book | 2.70 X | ||||
| Price To Sales | 4.65 X | ||||
| Revenue | 398.99 M | ||||
| Gross Profit | 40.55 M | ||||
| EBITDA | (234.57 M) | ||||
| Net Income | (257.1 M) | ||||
| Cash And Equivalents | 1.26 B | ||||
| Cash Per Share | 13.10 X | ||||
| Total Debt | 153.47 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 7.91 X | ||||
| Book Value Per Share | 6.87 X | ||||
| Cash Flow From Operations | (214.87 M) | ||||
| Earnings Per Share | (1.90) X | ||||
| Market Capitalization | 2.05 B | ||||
| Total Asset | 1.19 B | ||||
| Retained Earnings | (2.45 B) | ||||
| Working Capital | 751.1 M | ||||
About Zai Lab Performance
By analyzing Zai Lab's fundamental ratios, stakeholders can gain valuable insights into Zai Lab's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zai Lab has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zai Lab has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 113.20 | 107.54 | |
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.22) | (0.20) | |
| Return On Equity | (0.35) | (0.37) |
Things to note about Zai Lab performance evaluation
Checking the ongoing alerts about Zai Lab for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zai Lab help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zai Lab generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 398.99 M. Net Loss for the year was (257.1 M) with profit before overhead, payroll, taxes, and interest of 40.55 M. | |
| Zai Lab currently holds about 1.26 B in cash with (214.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.1. | |
| Latest headline from insidermonkey.com: UBS Gives Zai Lab a Buy Rating |
- Analyzing Zai Lab's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zai Lab's stock is overvalued or undervalued compared to its peers.
- Examining Zai Lab's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zai Lab's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zai Lab's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zai Lab's stock. These opinions can provide insight into Zai Lab's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zai Stock analysis
When running Zai Lab's price analysis, check to measure Zai Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zai Lab is operating at the current time. Most of Zai Lab's value examination focuses on studying past and present price action to predict the probability of Zai Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zai Lab's price. Additionally, you may evaluate how the addition of Zai Lab to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |